Interventional Cardiologist, CTO-PCI, CHIP, Peripheral vascular disease, acute PE. Views & opinions are my own.

Joined February 2021
232 Photos and videos
Ops check and Garmin database updates. #Outreach in Gillette, WY, Philip, SD, and hopefully another site in ND or NE within the next 2-3 months.
2
15
1,478
How to manage this? Elderly male, adm for PNA, on Abx, underlying ILD. Trop 6k, EF normal on Echo. EDP = 9. #stringsign @agtruesdell @drAliyor @cardiojaydoc02 @IntervnCardio @TomVargheseJr @DrIHHashmi1 @sandeep_jalli @realarainmd @jl35wilsonMD @Hragy @evandrofilhobr
6
3
16
6,276
Heading to work—beautiful sunrise. As an outpatient heart & vascular specialist, I travel to maintain acute MI/shock skills. #weekendwarrior
15
2,575
Tom Wilson retweeted
Healthcare administration costs should never exceed patient care costs.
33
177
635
66,460

504
Tom Wilson retweeted
Study conclusion: Angiography guided PCI was associated with significantly higher risk for MACE, However, IVI-guided PCI had comparable risk with CABG in DM patients. But there's a methodological concern hiding in the study design that the authors didn't discuss: Immortal time bias. 1/
Replying to @ihtanboga
Thank you for the wonderful explanation. Two (more!) naive questions about immortal time bias. With re: to this particular analysis, where CABG pts were part of a registry but the PCI cohorts were part of an RCT, is it fair to say that: 1) Immortal time bias should favor PCI (if at all) here since there was no delay to treatment in the CABG arm? Presumably the pts had surgery exactly at the start of the follow up period. 2) Immortal time bias is unlikely to explain the difference bet. angio and IVI guided PCI because the assigned treatment was delivered immediately after randomization? Perhaps there are other confounding factors to explain the early high event rate in the angio PCI arm? šŸ¤”
3
15
53
22,742
Tom Wilson retweeted
Replying to @drjohnm
I have been outspoken on the massive misuse of CAC testing for a long time (excerpt from my book in 2011) and have never ordered one.
32
30
126
165,343
Replying to @farkomd
@farkomd @_backtable @JayMathewsMD @DrRajeshG1 @KPujdak @realarainmd @cardiojaydoc02 @SripalBangalore @IR_Doctor 70M, h/o SMA aneurysm w surg repair x2 (2010/18) at tertiary care center. Back w ASx enlarging SMA aneurysm. Next step? Pt has not done well w/ Surgery. Endo option?
10
2
19
2,482
1
1
399
It’s always challenging seeing a patient for the last time. But encouraging to see a supportive and loving family helping a mother live graciously outside of a nursing home.

ALT Robin Williams Movie GIF

429
#cardiotwitter @cingolani_oscar @cardiojaydoc02 @CMichaelGibson @JayMathewsMD @AntoniousAttall @SrihariNaiduMD 60s Male see on ā€œurgentā€ basis. PA did CAC—6k. Told the patient ā€œ3000 in the widowmaker.ā€ Said Cath was needed. No clear Sx, was told to cancel Vacation w friends. Now I tell him at mos one could argue a stress test could be ordered. Had FHx as well. Now I’m accused of ā€œnot doing enoughā€ after spending 30m explaining everything about a CAC.
17
6
63
29,406
Tom Wilson retweeted
"The term [provider] should not be used to describe physicians, nor should physicians use it to describe themselves, their team members, or their trainees." acpjournals.org/doi/10.7326/… @AnnalsofIM @ACPIMPhysicians
92
416
1,682
286,603
1st RDN case in South Dakota, MT, WY. Resistant HTN is a killer. Lowering SBP by 10 mmHg makes a difference! Why hasn’t this become more mainstream? Reimbursement in all likelihood. Thank you @MedtronicCRDN. Simple, easy, quick. Both myself & @jl35wilsonMD at Black Hills Heart & Vascular are making 🌊. Thank you to the team at BHSH here in Rapid City, SD.
3
2
20
1,925
27 Nov 2025
Tyler Childress, Gavin Adcock, Tucker Westmore headlining the TG playlist tonight. What else to add? @jl35wilsonMD @txsportsdoc @Allison_Dupont @drjohnm @DrJayMohan @AntoniousAttall @AndrewJSauer
1
8
1,619
Tom Wilson retweeted
šŸš€ Calcium Score & CCTA: Key Highlights from the 2025 AHA Scientific Statement (DOI: 10.1161/CIR.0000000000001394) Non-obstructive CAD in Chest Pain Patients 🧊 1. CAC = Atherosclerotic Burden, Not Just a Number CAC is one of theĀ strongest predictorsĀ of future ASCVD risk—better than biomarkers or stenosis alone. šŸ“‰Ā CAC = 0 → high NPV for obstructive CAD (butĀ notĀ zero risk: ~10% still have non-calcified plaque, especially if young or high-risk). šŸ”„Ā CAC ≄1000Ā =Ā extreme risk → annual CV mortality similar to 2ndry prevention populations. šŸ“Š CAC → intensity of preventive therapy: from lifestyle (CAC 0) → to statins (CAC ≄100) → to high-intensity LLT aspirin (CAC ≄300). 🧮 2. CAC for Risk Upgrading & Therapy Decisions CAC ≄100 or ≄75th percentile supportsĀ starting statinsĀ even in borderline/intermediate-risk patients. - hidden high-risk phenotypes (eg, DM or preDM patients with CAC ≄100). 🌈 CAC fromĀ non-gated PET/SPECT CTĀ is increasingly used and correlates well with dedicated CAC scans. šŸ«€Ā 3. CCTA: The New Backbone of Chest Pain Evaluation The 2021 Chest Pain Guidelines expanded CCTA → leading to a surge in detectingĀ nonobstructive CAD (NOCA). CCTA is essential because: - plaque beyond the lumenĀ (including noncalcified plaque). - vessels down toĀ ~2 mmĀ (even smaller with photon-counting CT). -Ā high-risk plaque featuresĀ (LAP, positive remodeling, spotty calcification). šŸ‘ļø CCTA reveals thatĀ up to 50%Ā of symptomatic patients have NOCA. 🧨 4. High-Risk Plaque on CCTA = High Future Event Risk High-risk markers include: šŸ“¦ High total plaque volume 🟣 Low-attenuation plaque (>4%) āž• ≄2 high-risk features (per CAD-RADS 2.0) šŸ”„ Pericoronary adipose tissue (PCAT) inflammation These features predict MIĀ better than stenosis, shifting the paradigm from stenosis-centric to plaque-centric care. šŸ“ˆĀ 5. CCTA-Based Risk Staging (CAD-RADS 2.0 Plaque Volume) Stage 0 → no plaque Stage 1–2 → increasing plaque burden Stage 3 → high-risk NOCA šŸŽÆ Treatment intensity escalates with plaque volume, not stenosis alone. šŸ”„Ā 6. CAC CCTA = The Most Powerful Combination CAC quantifiesĀ calcifiedĀ burden → great for long-term risk and therapy escalation. CCTA quantifiesĀ totalĀ plaque (calcified noncalcified) → great for short-term event risk. šŸ’”Ā 7. Why This Matters Most ACS events originate fromĀ nonobstructiveĀ lesions. šŸ“¢ The statement pushes clinicians to: Detect early plaque (especially noncalcified). Classify risk by plaque burden inflammation. Intensify therapyĀ beforeĀ stenosis develops. #PCCT #Atherosclerosis #PhotonCountingCT #CCT #yesCCT
10
150
370
31,090
Tom Wilson retweeted
Ten-year outcome in the NOBLE trial šŸ«€Today, we presented that there is no difference in all-cause mortality ten years after randomization to PCI or CABG in patients with unprotected LMCA disease. For more info contact @h_evald or me - always eager to interact!
6
24
85
5,978
Tom Wilson retweeted
15 Oct 2025
šŸ“–#Transradial access is viable & potentially superior alternative to femoral or brachial access for #PVI, offering reduced complication rates and enhanced patient outcomes #RadialFirst In 137 patients (213 lesions): āœ… 98.5% procedural success āœ… 2.1% complication rate āœ… 96.5% same-day discharge āž”ļøjscai.org/article/S2772-9303… @fuadfehmi @MohamedOsmanMD #PeripheralVascularIntervention
1
19
63
6,067
3 Sep 2025
Where can I find a high quality white coat? Most (nearly all) are polyester, of poor quality, and uncomfortable. I don’t use them every day but still need one. #cardiotwitter
1
4
642
Tom Wilson retweeted
Practice-changing meta-analysis presented by ⁦@vlgmrc⁩ at #ESCCongress2025 and published in ⁦@TheLancet⁩.
8
81
304
36,249
15 Aug 2025
Morning commute. 0500 departure. Always a privilege to watch the sunrise at FL210. Maybe catch the sunset on the way back home?
1
5
723